These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 16405543)

  • 1. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease.
    Henderson S; Hoffman N; Prince R
    Am J Gastroenterol; 2006 Jan; 101(1):119-23. PubMed ID: 16405543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
    Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
    Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
    Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
    Hooper MJ; Ebeling PR; Roberts AP; Graham JJ; Nicholson GC; D'Emden M; Ernst TF; Wenderoth D
    Climacteric; 2005 Sep; 8(3):251-62. PubMed ID: 16390757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
    van Bodegraven AA; Bravenboer N; Witte BI; Dijkstra G; van der Woude CJ; Stokkers PC; Russel MG; Oldenburg B; Pierik M; Roos JC; van Hogezand RA; Dik VK; Oostlander AE; Netelenbos JC; van de Langerijt L; Hommes DW; Lips P;
    Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of risedronate on bone metabolism after total hip arthroplasty: a prospective randomised study.
    Kinov P; Tivchev P; Doukova P; Leithner A
    Acta Orthop Belg; 2006 Jan; 72(1):44-50. PubMed ID: 16570894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risedronate therapy for prevention of hip fracture after stroke in elderly women.
    Sato Y; Iwamoto J; Kanoko T; Satoh K
    Neurology; 2005 Mar; 64(5):811-6. PubMed ID: 15753414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Cohen S; Levy RM; Keller M; Boling E; Emkey RD; Greenwald M; Zizic TM; Wallach S; Sewell KL; Lukert BP; Axelrod DW; Chines AA
    Arthritis Rheum; 1999 Nov; 42(11):2309-18. PubMed ID: 10555025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly risedronate in kidney transplant patients with osteopenia.
    Torregrosa JV; Fuster D; Pedroso S; Diekmann F; Campistol JM; Rubí S; Oppenheimer F
    Transpl Int; 2007 Aug; 20(8):708-11. PubMed ID: 17555530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.
    Sköldenberg OG; Salemyr MO; Bodén HS; Ahl TE; Adolphson PY
    J Bone Joint Surg Am; 2011 Oct; 93(20):1857-64. PubMed ID: 22012522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pathological bone density in chronic inflammatory bowel diseases--prevalence and risk factors].
    Von Tirpitz C; Pischulti G; Klaus J; Rieber A; Brückel J; Böhm BO; Adler G; Reinshagen M
    Z Gastroenterol; 1999 Jan; 37(1):5-12. PubMed ID: 10091278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal morbidity in inflammatory bowel disease.
    van Hogezand RA; Hamdy NA
    Scand J Gastroenterol Suppl; 2006; (243):59-64. PubMed ID: 16782623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis.
    Bernstein CN; Seeger LL; Sayre JW; Anton PA; Artinian L; Shanahan F
    J Bone Miner Res; 1995 Feb; 10(2):250-6. PubMed ID: 7754804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
    Delmas PD; McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S
    Bone; 2008 Jan; 42(1):36-42. PubMed ID: 17920005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bone loss owing to inflammatory bowel disease: prospective study, 50 cases].
    Ben Hamida KS; Serghini M; Ksontini I; Kedadi H; Ben Yaghléne L; Bougassas W; Dougui MH
    Tunis Med; 2009 Feb; 87(2):144-8. PubMed ID: 19522449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Osteoporosis and inflammatory bowel disease: prevalence and risk factors in Tunisian patients].
    Boubaker J; Feki M; Hsairi M; Fekih M; Kaabachi N; Filali A; Mebazaa A
    Gastroenterol Clin Biol; 2003 Oct; 27(10):901-7. PubMed ID: 14631305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risedronate: clinical usage.
    Chapurlat RD; Delmas PD
    Int J Clin Pract; 2001 May; 55(4):275-8. PubMed ID: 11406915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
    Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.